CRP and inflammatory bowel disease: Lastly, progress in IBD management has changed the treatment approach significantly more in the present era because of the introduction of biomarkers, personalized medicine, and associated targeted biologics that enable better disease modulation and ultimate patient outcomes. The diagnostics and status of inflammatory and serum biomarkers, such as C-reactive protein (CRP) and fecal calprotectin, are essential in monitoring disease activity and guiding treatment decisions in IBD.